Table 1.
Patient characteristics.
| Patients, N | 28 | |
|---|---|---|
| Patients with β-thalassemia, N | 22 | |
| Patients with onco-hematologic disease, N | 6 | |
| Male, N (%) | 15 (53.5) | |
| Age, Median (IQR) | 43 (34–52) | |
| HCV genotype | 1b (100) | |
| Patients with available rs12979860 IL-28B genotype, N (%) | ||
| CC | 14 (50.0) | |
| CT | 11 (39.2) | |
| TT | 2 (7.1) | |
| Unknown | 1 (3.5) | |
| Acute Infection, N (%) | 17 (61) | |
| Diagnosis of Acute Infection, Year | 2016 | |
| Chronic Infection, N (%) | 11 (39) | |
| Naive * | 27 | |
| HCV-RNA (logIU/mL), Median (IQR) | 4.9 (3.3–6.0) | |
| AST (IU/mL), Median (IQR) ** | 271 (85–547) | |
| ALT (IU/mL), Median (IQR) ** | 485 (255–718) | |
* 1 patient failed a DAA-based regimen for HCV. ** Values were calculated according to the information available (only for patients with acute infection). Abbreviations: IQR, interquartile range; IU, international unit; AST, aspartate aminotransferase; ALT, alanine aminotransferase.